<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the widespread use of herbal medicine among oncology patients, some with potentially harmful effects, it has been shown that, in as many as 50% of cases, these patients are not telling their oncology health care professional (HCP), especially oncologists and pharmacists, that they are doing so [
 <xref rid="B6-pharmaceuticals-13-00455" ref-type="bibr">6</xref>]. There are a number of reasons for this lack of disclosure, including the assumption that herbal medicine use is not relevant to their oncology treatment or that their oncology HCPs lack any knowledge on this practice and, therefore, cannot provide any guidance on their use [
 <xref rid="B7-pharmaceuticals-13-00455" ref-type="bibr">7</xref>]. Patients may also anticipate a negative or dismissive response from their oncology HCPs, although, in many cases, they are simply not asked [
 <xref rid="B8-pharmaceuticals-13-00455" ref-type="bibr">8</xref>,
 <xref rid="B9-pharmaceuticals-13-00455" ref-type="bibr">9</xref>]. It has been shown that many oncology HCPs are unaware of the potentially harmful outcomes associated with the use of herbal medicine during active cancer care, making it difficult for them to help their patients make an informed decision on the benefits and risks of this practice [
 <xref rid="B10-pharmaceuticals-13-00455" ref-type="bibr">10</xref>].
</p>
